Close

medmix Drug Delivery (Haselmeier™) and AARDEX® Group Join Forces to Improve Self-Administration of Injectable Drugs in Clinical Trials

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Phesi announces AI-driven Trial Accelerator platform hits new milestone with data from 132 million patients

Boston, US: Phesi, a global provider of patient-centric data analytics, has...

Upperton completes build of new £7m sterile manufacturing facility

Nottingham - Leading UK contract development and manufacturing organisation (CDMO)...

Oncology start-ups urged to apply and accelerate their business with Discovery Spark

Applications open for Discovery Park’s oncology themed ‘Discovery...

medmix Drug Delivery (Haselmeier) and AARDEX Group announced a collaboration, combining Haselmeier´s D-Flex™ Logbook with AARDEX Group’s Medication Adherence software and hardware ecosystem.

Clinical testing during new drug development is costly and time intensive for pharmaceutical and biotech companies. The need for solutions, helping them to shorten testing time and increase data quality are two of the main factors determining overall cost and success of newly developed drugs. As a result, the future of clinical trials is becoming more reliant on connected medical devices, collecting data at the point of care, reducing the need for costly patient visits and cumbersome manual data acquisition. Therefore, Haselmeier, a medmix Brand, and AARDEX Group have joined forces to tackle the challenge of managing patient adherence during clinical trials.

Haselmeier developed the D-Flex Logbook, a wireless connected drug delivery solution. Now this solution can be easily integrated into AARDEX Group’s adherence software, MEMS AS®. This electronic data capture system has been successfully utilized to collect patient adherence data from digitally enabled devices such as pillboxes and drug containers for over 20 years. The combination of the two systems allows researchers to understand and manage patient adherence in clinical trials testing self-injection therapies.

Given AARDEX Group’s and Haselmeier´s decades long experience in the pharma industry, the collaboration comes naturally, complementing one another’s offering in clinical testing. This evidence-based approach can make the difference between failed and successful clinical trials.

Latest stories